Catalog No.
Product Name
Application
Product Information
Citations
-
Reverse Transcriptase Inhibitor
Mniopetal B is a reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound demonstrates significant biological activity by interfering with the reverse transcription process, which is critical for the replication of retroviruses. Its mechanism makes Mniopetal B suitable for research applications focused on virology, HIV studies, and the development of antiviral therapies. -
Reverse Transcriptase Inhibitor
Mniopetal D is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound demonstrates significant biological activity by blocking the reverse transcription process, which is essential in the life cycle of retroviruses. Mniopetal D is utilized in research applications focused on antiviral drug development and understanding retroviral replication mechanisms. -
Reverse Transcriptase Inhibitor
Mniopetal F is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. It effectively disrupts the replication cycle of retroviruses by hindering the reverse transcription process, making it a valuable tool in antiviral research. Mniopetal F can be utilized in studies focused on understanding viral mechanisms and developing therapeutic strategies against retroviral infections. -
Reverse Transcriptase Inhibitor
NNRT-IN-5 is a non-nucleoside reverse transcriptase inhibitor that exhibits potent antiviral activity against HIV. This compound functions by binding to the reverse transcriptase enzyme, disrupting the viral replication process. NNRT-IN-5 is primarily utilized in research to explore HIV mechanisms and develop novel therapeutic strategies targeting reverse transcriptase. -
Reverse Transcriptase Inhibitor
Mniopetal C is a reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound exhibits significant biological activity by disrupting the reverse transcription process, making it valuable for research in molecular biology and virology. Mniopetal C can be utilized in studies focused on retroviral infections and the development of antiretroviral therapies. -
Reverse Transcriptase Inhibitor
Mniopetal A is a potent reverse transcriptase inhibitor derived from Mniopetalum sp. 87256. This compound has demonstrated significant ability to impede the reverse transcription process, making it a valuable tool in research focused on retroviral infections and related mechanisms. Its application extends to studies investigating viral replication, cellular responses to viral entry, and therapeutic developments targeting reverse transcription pathways. -
HIV-1 reverse transcriptase Inhibitor
Ulonivirine is an orally active non-nucleoside inhibitor of HIV-1 reverse transcriptase, targeting the hydrophobic binding pocket adjacent to the enzyme's polymerase active site. It effectively disrupts viral replication, making it a valuable tool for research focused on HIV-1 infection and the mechanisms of antiretroviral resistance. Ulonivirine is suitable for studies aimed at understanding HIV-1 pathogenesis and developing therapeutic interventions. -
Nucleoside Reverse Transcriptase Inhibitor
Rovafovir etalafenamide is a prodrug of the adenosine nucleotide analogue GS-9148, functioning as a nucleoside reverse transcriptase inhibitor (NRTI). It demonstrates significant potency against a range of NRTI-resistant HIV-1 mutations, making it an important tool in HIV research. Its effective anti-HIV-1 activity positions it as a valuable compound for studies aimed at understanding viral resistance mechanisms and the development of therapeutic strategies. -
Nonnucleoside Reverse Transcriptase Inhibitor
IQP-0528 is a potent nonnucleoside reverse transcriptase inhibitor (NNRTI) that effectively targets HIV-1 and HIV-2. It demonstrates remarkable potency with EC50 values of 0.2 nM for HIV-1 and 100 nM for HIV-2. This compound is primarily utilized in research focused on the development of antiviral therapies and the study of HIV replication mechanisms. -
HIV-1 Reverse Transcriptase Inhibitor/μ-opioid Receptor Agonist
Corydine targets HIV-1 reverse transcriptase and the μ-opioid receptor, acting as an inhibitor with an IC50 of 356.7 μg/mL against the enzyme and an EC50 of 0.51 μM at the receptor. It exhibits antinociceptive effects through the modulation of MOR, effectively reducing acetic acid-induced writhing behavior. Corydine has also demonstrated the ability to inhibit the proliferation of various cancer cells and immune cells, making it a valuable reagent for research into HIV infection, visceral pain, and various cancers including leukemia, melanoma, bladder cancer, and colon adenocarcinoma. -
HIV-1 Reverse Transcriptase Inhibitor
Reverse transcriptase-IN-1 is a potent inhibitor of HIV-1 reverse transcriptase, classified as a diarylbenzopyrimidine (DABP) analogue. It exhibits significant antiviral activity, with effective concentration (EC50) values of 3.4 nM, 4.3 nM, and 3.6 nM against HIV-1 strains IIIB, E138K, and K103N, respectively. Additionally, it demonstrates an inhibitory concentration (IC50) of 13.7 nM on the HIV-1 reverse transcriptase enzyme, making it a valuable tool for research in HIV therapeutic development. -
Non-nucleoside Reverse Transcriptase Inhibitor
Talviraline is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that targets the HIV-1 reverse transcriptase enzyme, effectively hindering the replication of human immunodeficiency virus type 1 (HIV-1). By binding to a distinct site on the enzyme, Talviraline disrupts the viral replication process. This compound serves as a valuable tool for researching antiviral strategies and assessing the safety and efficacy of potential therapies against HIV-1 infection. -
HIV-1 Reverse Transcriptase Inhibitor
Atevirdine is a potent non-nucleoside HIV-1 reverse transcriptase inhibitor that specifically targets the reverse transcriptase enzyme. By inhibiting this enzyme, Atevirdine effectively disrupts viral replication, thereby reducing HIV-1 viral load. This compound is useful in research focused on HIV-1 treatment strategies and the development of antiretroviral therapies. -
Non-nucleotide HIV Reverse Transcriptase Inhibitor
Ainuovirine is a second-generation non-nucleoside HIV reverse transcriptase inhibitor (NNRTI) that targets HIV reverse transcriptase. By non-competitively binding to the enzyme, Ainuovirine effectively disrupts the reverse transcription of viral RNA, thereby inhibiting HIV replication. This compound is utilized in research focused on human immunodeficiency virus (HIV) type 1 infection. -
HIV-1 Reverse Transcriptase Inhibitor
HI-236 is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase, effectively disrupting the replication of the HIV virus. It demonstrates exceptional antiviral activity, with an IC50 value of less than 0.001 μM against wild-type HTLVIIIB. This compound is primarily utilized in HIV research, particularly in the development of antiretroviral therapies. -
HIV-1 Reverse Transcriptase Inhibitor
Urushiol (15:3) is an inhibitor of HIV-1 reverse transcriptase, demonstrating moderate inhibitory activity with an IC50 value of 55.36 μM. This compound, derived from the leaves of Rhus verniciflua, exhibits significant cytotoxicity against prostate cancer PC-3 cells and normal MRC-5 cells. Urushiol (15:3) is relevant for research into anti-HIV-1 therapies and the study of prostate cancer biology. -
Reverse Transcriptase
Etravirine-d4 is a deuterium-labeled analog of Etravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV reverse transcriptase. This compound is utilized in research to study the mechanisms of HIV inhibition and resistance. Etravirine-d4 is particularly valuable for pharmacokinetic studies and metabolic profiling in antiviral research. -
Non-nucleoside Reverse Transcriptase Inhibitor
Capravirine is an orally active non-nucleoside reverse transcriptase inhibitor (NNRTI) primarily targeting the HIV-1 reverse transcriptase enzyme. It demonstrates potent antiviral activity against various strains of HIV-1, including those resistant to both nucleoside/nucleotide reverse transcriptase inhibitors and other NNRTIs. Capravirine is metabolized by the cytochrome P450 enzyme CYP3A4, making it relevant for studies on drug interactions and resistance mechanisms in HIV research. -
Reverse Transcriptase Inhibitor
Inophyllum B is a potent inhibitor of HIV reverse transcriptase, exhibiting an impressive IC50 value of 38 nM. This compound effectively inhibits HIV-1 in vitro cell cultures with an IC50 of 1.4 μM. Inophyllum B is isolated from the acetone extract of the giant African snail, Achatina fulica, making it a valuable reagent for research applications focused on antiviral drug development and the mechanisms of HIV replication. -
Non-Nucleoside rReverse Transcriptase Inhibitor
UC-84 (NSC-615985) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits potent anti-HIV activity. By targeting the reverse transcriptase enzyme, UC-84 effectively disrupts viral replication, making it a valuable compound for HIV research. Its application extends to studies focused on the mechanisms of viral resistance and the development of novel therapeutic strategies against HIV. -
Non-Nucleoside rReverse Transcriptase Inhibitor
UC-38 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits potent anti-HIV activity. This compound disrupts the reverse transcription process essential for the viral replication cycle, making it a valuable tool for research on HIV mechanisms and potential therapeutics. Its application extends to the investigation of NNRTIs in the development of effective HIV treatment strategies. -
Non-Nucleoside reverse Transcriptase Inhibitor
Bavtavirine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) that targets the reverse transcriptase enzyme essential for HIV replication. It is utilized in highly active antiretroviral therapy (HAART) regimens and has significant implications in HIV disease research. Bavtavirine's mechanism of action makes it a valuable tool in studying HIV pathogenesis and developing therapeutic strategies against the virus. -
Reverse Transcriptase Inhibitor
HIV-1 inhibitor-56 functions as a potent non-nucleoside reverse transcriptase inhibitor targeting the HIV-1 virus. It exhibits significant antiviral activity against wild-type HIV-1 in TZM cells, with an EC50 value of 0.24 nM, indicating strong efficacy. Additionally, HIV-1 inhibitor-56 is capable of penetrating the blood-brain barrier, making it a valuable tool for research in HIV-1-related neurological studies and therapeutic development. -
Reverse Transcriptase Inhibitor
Dexelvucitabine is a potent nucleoside reverse transcriptase inhibitor that targets HIV-1 polymerase. This orally active compound exhibits efficacy against HIV-1 strains resistant to thymidine analogs and those harboring the M184V mutation. As a 2′-deoxycytidine analog, Dexelvucitabine serves as an important research tool for studying antiretroviral therapies and the mechanisms of drug resistance in viral infections. -
HIV-1 Reverse Transcriptase Inhibitor
Thiazolobenzimidazole is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. It effectively inhibits HIV-induced cytotoxicity and viral replication in various human cell lines, making it a valuable compound for research on HIV therapy and antiviral drug development. Its mechanism of action offers insights into potential therapeutic strategies against HIV-1 infection. -
Reverse Transcriptase Inhibitor
(+)-Dihydrocalanolide A is a non-nucleoside inhibitor of Reverse Transcriptase, exhibiting oral bioactivity. This compound demonstrates significant inhibitory effects on HIV replication and is valuable in research investigating HIV infection mechanisms and potential therapeutic strategies. Its pharmacological profile supports its use in studies aimed at understanding antiviral activities and developing new HIV treatments. -
HIV-1 Reverse Transcriptase Inhibitor
L 697661 is an orally active inhibitor of HIV-1 reverse transcriptase, targeting the essential enzyme required for the replication of the virus. This compound demonstrates potent antiviral activity against HIV-1, making it a valuable tool for research in HIV treatment and therapies. Its ability to interrupt viral replication pathways provides critical insights into antiviral drug development and therapeutic efficacy studies. -
Reverse Transcriptase Inhibitor
BILR 355 is a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) that specifically targets HIV-1 reverse transcriptase. This compound demonstrates potent inhibition of viral replication, making it a valuable tool for research on HIV infections and the development of antiviral therapies. BILR 355's selectivity and effectiveness in disrupting reverse transcription make it an important reagent for studying HIV biology and drug resistance. -
HIV-1 Reverse Transcriptase Inhibitor
U 88204 is a potent inhibitor of HIV-1 reverse transcriptase, exhibiting an IC50 value of 0.25 μM. This compound effectively blocks the replication of HIV-1 in infected cells, making it a valuable tool for research focused on HIV infection and acquired immunodeficiency syndrome (AIDS). Its specificity and efficacy facilitate studies aimed at understanding the mechanisms of viral replication and the development of antiviral therapies. -
Nucleoside Reverse Transcriptase Inhibitor
Amdoxovir is a nucleoside reverse transcriptase inhibitor that acts as a prodrug of dioxolane guanosine. It demonstrates efficacy against both wild-type and nucleoside reverse transcriptase inhibitor-resistant HIV strains. Amdoxovir is utilized in research related to HIV/AIDS, providing insight into antiviral mechanisms and potential therapeutic strategies. -
HIV-1 Reverse Transcriptase Inhibitor
BRN3OMe is a potent inhibitor of HIV-1 reverse transcriptase, specifically targeting the enzyme essential for the replication of the HIV-1 virus. This compound demonstrates significant antiviral activity, making it a valuable tool in the study of HIV replication and the development of antiviral agents. Researchers may utilize BRN3OMe to explore mechanisms of inhibition and therapeutic applications in HIV treatment strategies. -
HIV-1 Reverse Transcriptase Ribonuclease H Inhibitor
GSK5750 is a specific and potent inhibitor of HIV-1 reverse transcriptase ribonuclease H, exhibiting an IC50 value of 0.33 μM. This compound functions through a metal-ion chelation mechanism at the RNase H active site. GSK5750 is valuable for research into HIV replication and the development of antiviral strategies targeting reverse transcriptase. -
Non-nucleoside Reverse Transcriptase Inhibitor
DC20 is a potent non-nucleoside reverse transcriptase inhibitor targeting HIV-1, exhibiting an EC50 of 0.004 μM against the HIV-1IIIB strain. This compound demonstrates significant antiviral activity, making it a valuable tool in the study and treatment of HIV infections. Its efficacy positions DC20 as a critical reagent for research in antiviral drug development and mechanisms of HIV resistance. -
Non-nucleoside Reverse Transcriptase Inhibitor
RDEA 806 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that demonstrates potent inhibitory activity against both wild-type and NNRTI-resistant HIV-1 strains, with an EC50 of 3.05 nM. This compound's selective action on reverse transcriptase makes it a valuable tool for studying HIV replication and developing antiviral therapies. Research applications include evaluating resistance patterns and assessing the efficacy of combination treatments in HIV research. -
HIV-1 Reverse Transcriptase Inhibitor
Melanochromone is an inhibitor of HIV-1 reverse transcriptase, demonstrating significant anti-HIV-1 activity. This compound is utilized in research focusing on HIV-1 infection and its mechanisms, contributing to the understanding of viral replication and potential therapeutic interventions. -
Reverse Transcriptase Inhibitor
PNU-103657 is an orally active reverse transcriptase inhibitor, demonstrating an IC50 value of 0.51 μM against wild-type enzyme. This compound exhibits significant antiviral activity, making it a valuable tool in research targeting viral infections, particularly in the context of HIV and related immune system disorders. -
HIV-1 Reverse Transcriptase Inhibitor
DPC-082 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. It demonstrates significant antiviral activity, with an IC90 of 2.0 nM against wild-type RF virus. Additionally, DPC-082 effectively inhibits a variety of single and multiple amino acid substituted HIV-1 mutant strains, making it a valuable tool for research into HIV resistance mechanisms and therapeutic development. -
Reverse Transcriptase Inhibitor
Niglizin is a noncompetitive inhibitor of reverse transcriptase, demonstrating significant efficacy in suppressing HIV replication. This compound exhibits a synergistic effect when used in conjunction with Zidovudine, enhancing its antiviral activity. Niglizin is valuable for research applications focused on HIV infection and the development of antiretroviral therapies. -
HIV-1 Reverse Transcriptase Inhibitor
HI-280 is an HIV-1 reverse transcriptase inhibitor that disrupts the replication cycle of the virus. Its primary mechanism involves targeting the reverse transcriptase enzyme, critical for the transcription of viral RNA into DNA. HI-280 holds potential for research applications focused on the mechanisms of HIV infection and the development of antiretroviral therapies. -
Non-nucleoside Reverse Transcriptase Inhibitor
VRX-480773 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high specificity for HIV-1, demonstrating an EC50 of 0.14 nM against wild-type strains. This compound exhibits no inhibitory effects on HIV-2, HBV, or HCV, and does not affect human DNA polymerase α/β. Additionally, VRX-480773 maintains efficacy against Efavirenz-resistant HIV-1 variants, with EC50 values generally below 1 nM. Its unique properties make it a valuable tool for research into HIV/AIDS. -
Non-nucleoside Reverse Transcriptase Inhibitor
HI-207 is a non-nucleoside reverse transcriptase inhibitor with demonstrated anti-HIV activity. It exhibits an IC50 value of 0.27 μM in PBMC/p24 inhibition assays, making it a potent candidate for studies investigating HIV infection mechanisms and therapeutic interventions. This compound is useful for researchers focusing on antiviral drug development and the modulation of HIV replication. -
HIV-1 Reverse Transcriptase Inhibitor
R-82150 is an HIV-1 reverse transcriptase inhibitor that functions by binding to the non-substrate binding site of the reverse transcriptase enzyme, effectively blocking the reverse transcription of viral RNA. This mechanism inhibits viral replication in HIV-1, while showing no effect on HIV-2, other RNA viruses, or DNA viruses. R-82150 is primarily utilized in research focused on understanding HIV-1 replication and therapeutic interventions. -
Nucleoside Reverse Transcriptase Inhibitor
Lamivudine-13C,15N2 is a labeled impurity of Lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI). This compound effectively inhibits the reverse transcriptase activity of HIV-1 and HIV-2, as well as that of the hepatitis B virus, making it valuable in antiviral research. It is utilized in studies aiming to understand the pharmacokinetics and metabolic pathways of Lamivudine and its derivatives. -
HIV-1 Reverse Transcriptase Inhibitor
Mesoxalate, a dicarboxylic and ketonic acid, serves as an inhibitor of HIV-1 reverse transcriptase (RT). It exerts biological activity with an IC50 value of 2.2 μM, making it a valuable tool for studying the inhibition of HIV replication. Mesoxalate is applicable in research focusing on antiviral therapies targeting retroviral enzymes. -
HIV-1 Reverse Transcriptase Inhibitor
L-702007 is a potent inhibitor of HIV-1 reverse transcriptase, a critical enzyme in the life cycle of the HIV virus. By obstructing viral replication, it exhibits significant antiviral activity, making it a valuable tool in HIV research. This compound is instrumental in studying the mechanisms of HIV infection and testing potential antiviral therapies. -
HIV-1 Reverse Transcriptase Inhibitor
NNRT-IN-10 is a potent, selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, demonstrating EC50 values ranging from 1.16 to 18.3 nM against HIV and its mutant strains. This compound exhibits favorable pharmacokinetic properties and safety profiles, making it suitable for research applications in studying HIV-1 and AIDS. NNRT-IN-10 represents a crucial tool for advancing antiviral research targeting HIV-1 replication. -
HIV-1 Reverse Transcriptase Inhibitor
TSAO-T is a potent inhibitor of HIV-1 reverse transcriptase, a key enzyme in the retroviral replication cycle. By disrupting this enzyme's activity, TSAO-T effectively impedes viral replication, making it a valuable tool in HIV research. Its use can facilitate the study of HIV infection mechanisms and the development of novel therapeutic strategies. -
Non-Nucleoside Reverse Transcriptase Inhibitor
DPC 961 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that specifically targets HIV-1 reverse transcriptase. It exerts its biological activity by non-competitively inhibiting the enzymatic function of reverse transcriptase, effectively blocking viral replication. This compound is primarily utilized in research focused on AIDS and the mechanisms of HIV pathogenesis. -
Non-nucleoside Reverse Transcriptase Inhibitor
DPC 963 is an oral active non-nucleoside reverse transcriptase inhibitor that demonstrates an IC50 of 18 nM. This compound is primarily utilized in the study of HIV, providing insights into reverse transcription processes and potential therapeutic strategies. Its potent inhibitory activity makes DPC 963 a valuable tool for research in antiviral drug development and HIV pathogenesis. -
HIV-1 nucleotide reverse transcriptase Inhibitor
GS-9148 is a ribose-modified inhibitor of HIV-1 nucleotide reverse transcriptase, exhibiting an EC50 value of 10.6 µM. This compound demonstrates significant antiretroviral activity against HIV-1 strains with mutations at K65R, L74V, and M184V. GS-9148 is a valuable tool for research focused on HIV resistance mechanisms and the development of novel therapeutic strategies.
